2.855
price up icon9.81%   0.255
after-market Handel nachbörslich: 2.86 0.005 +0.18%
loading

Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten

pulisher
Mar 04, 2026

CNTX SEC FilingsContext Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 04, 2026
pulisher
Mar 03, 2026

CNTX: Advancing three T-cell engager programs in solid tumors with key data milestones ahead - TradingView

Mar 03, 2026
pulisher
Mar 03, 2026

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 03, 2026
pulisher
Mar 03, 2026

OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI

Mar 03, 2026
pulisher
Mar 02, 2026

UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka

Mar 02, 2026
pulisher
Mar 02, 2026

CNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026
pulisher
Feb 28, 2026

CNTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026
pulisher
Feb 28, 2026

Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Sell - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

Context Therapeutics Reaches Governance Settlement, Plans Annual Elections - The Globe and Mail

Feb 28, 2026
pulisher
Feb 28, 2026

CNTX Should I Buy - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

Context Therapeutics (NASDAQ: CNTX) targets annual director elections in governance shift - Stock Titan

Feb 27, 2026
pulisher
Feb 26, 2026

Equities Analysts Issue Forecasts for CNTX FY2025 Earnings - Defense World

Feb 26, 2026
pulisher
Feb 25, 2026

Research Analysts Offer Predictions for CNTX FY2025 Earnings - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka

Feb 25, 2026
pulisher
Feb 25, 2026

Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital - Defense World

Feb 25, 2026
pulisher
Feb 24, 2026

Lifesci Capital Upgrades Context Therapeutics (NASDAQ:CNTX) to "Strong-Buy" - MarketBeat

Feb 24, 2026
pulisher
Feb 23, 2026

Context Therapeutics (CNTX) awards 270,000 stock options to Chief Legal Officer - Stock Titan

Feb 23, 2026
pulisher
Feb 23, 2026

CFO at Context Therapeutics (CNTX) receives 275,000-share stock option grant - Stock Titan

Feb 23, 2026
pulisher
Feb 23, 2026

Context Therapeutics (CNTX) CEO granted 815,000 stock options - Stock Titan

Feb 23, 2026
pulisher
Feb 20, 2026

What is Context Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Target Return Focused Stock Picks - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - MSN

Feb 20, 2026
pulisher
Feb 20, 2026

Is Context Therapeutics Inc. a potential multi bagger2025 Technical Patterns & Smart Money Movement Tracker - mfd.ru

Feb 20, 2026
pulisher
Feb 19, 2026

Shorts Report: Is H2O America stock forming a triangle patternQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 19, 2026

Geopolitics Watch: Whats the fair value of TMHC stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 19, 2026

Profit Recap: What is Context Therapeutics Incs book value per shareJuly 2025 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 17, 2026

Fund Flows: How does Context Therapeutics Inc perform in inflationary periodsEarnings Recap Summary & High Yield Stock Recommendations - baoquankhu1.vn

Feb 17, 2026
pulisher
Feb 17, 2026

Great Point reveals 5.1% Context Therapeutics (CNTX) stake in 13G/A - Stock Titan

Feb 17, 2026
pulisher
Feb 16, 2026

Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN

Feb 16, 2026
pulisher
Feb 16, 2026

Earnings Report: Is Klaviyo Inc attractive for institutional investorsLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn

Feb 16, 2026
pulisher
Feb 16, 2026

Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat

Feb 16, 2026
pulisher
Feb 14, 2026

How cyclical is Context Therapeutics Inc.’s revenue streamProfit Target & Real-Time Buy Signal Notifications - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Bank Watch: Does ABRPRD have pricing powerPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn

Feb 14, 2026
pulisher
Feb 14, 2026

Is WisdomTree Europe Hedged Equity Fund stock among top earnings playsJuly 2025 Price Swings & Comprehensive Market Scan Reports - mfd.ru

Feb 14, 2026
pulisher
Feb 14, 2026

Will AGF A S (5IN) stock return to pre crash levelsQuarterly Growth Report & Smart Swing Trading Alerts - mfd.ru

Feb 14, 2026
pulisher
Feb 12, 2026

ALNA Allena Pharmaceuticals NASDAQ Intraday 12 Feb 2026: Volume up at $0.075 - Meyka

Feb 12, 2026
pulisher
Feb 10, 2026

Context Therapeutics to Participate in Upcoming Investor Conferences - The Globe and Mail

Feb 10, 2026
pulisher
Feb 10, 2026

SYNI stock: Synvista Therapeutics (PNK) $0.000001 on 10 Feb 2026, oversold bounce - Meyka

Feb 10, 2026
pulisher
Feb 09, 2026

Biotech firm Context Therapeutics lines up four investor conferences - Stock Titan

Feb 09, 2026
pulisher
Feb 08, 2026

Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen - Defense World

Feb 08, 2026
pulisher
Feb 08, 2026

Compass Therapeutics (NASDAQ:CMPX) Cut to “Sell” at Wall Street Zen - Defense World

Feb 08, 2026
pulisher
Feb 07, 2026

Market Wrap: Is PARR forming a breakout pattern2025 Market Sentiment & Stepwise Trade Signal Guides - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 07, 2026

E.On (FRA:EOAN) Shares Cross Above 200 Day Moving Average – What’s Next? - Defense World

Feb 07, 2026
pulisher
Feb 06, 2026

Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka

Feb 06, 2026
pulisher
Feb 06, 2026

ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst - Meyka

Feb 06, 2026
pulisher
Feb 06, 2026

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Feb 06, 2026
pulisher
Feb 06, 2026

Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Aug Spikes: What is Context Therapeutics Incs book value per share2025 Sector Review & Expert Verified Stock Movement Alerts - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 05, 2026

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Yahoo Finance

Feb 05, 2026
pulisher
Feb 05, 2026

THCT stock rises 4,650% to $0.019 on PNK: short-term volume spike flags high volatility - Meyka

Feb 05, 2026
pulisher
Feb 04, 2026

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz

Feb 04, 2026
pulisher
Jan 28, 2026

Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo

Jan 28, 2026
pulisher
Jan 28, 2026

TELA Bio Grants Equity to New Hires as Medtech Growth Push Continues - mychesco.com

Jan 28, 2026
pulisher
Jan 28, 2026

Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com

Jan 28, 2026
pulisher
Jan 27, 2026

Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo

Jan 27, 2026
pulisher
Jan 24, 2026

Ideas Watch: How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn

Jan 24, 2026
pulisher
Jan 24, 2026

How does Context Therapeutics Inc compare to its peersWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn

Jan 24, 2026
pulisher
Jan 24, 2026

Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - Sahm

Jan 24, 2026
pulisher
Jan 23, 2026

JonesTrading Sticks to Its Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail

Jan 23, 2026
pulisher
Jan 23, 2026

Sarepta Therapeutics, Inc. (SRPT) stock: surges after-hours ahead of key Phase 3 results webcast - parameter.io

Jan 23, 2026
pulisher
Jan 23, 2026

Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player - mychesco.com

Jan 23, 2026
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.54
price down icon 4.23%
biotechnology ONC
$292.94
price down icon 2.03%
Kapitalisierung:     |  Volumen (24h):